SUMMARY: The “goodwill” that many believe was gained from the development of a Covid-19 may be more of a wish than a reality. Pharma companies are still too focused on profits while people continue to rely on prescription drugs to compensate for unhealthy lifestyles.
KEY TAKEAWAY: A study in JAMA found “a Markov cohort state-transition model determined that adding evolocumab at current list price to patients receiving standard background therapy was estimated to cost $268 637 per quality-adjusted life-year gained. Sensitivity and scenario analyses demonstrated incremental cost-effectiveness ratios ranging from $100 193 to $488 642 per quality-adjusted life-year.” Will this be enough to sway insurers to say “ok”?
In the past, when we bought new software, you would receive thick instruction books included with your purchase. There was just one problem, users rarely read the manuals and only referred to them when they had questions. So why would any company think that over 200 pages in update notes would be read by physicians and office staff who are time stressed?